Ann W Morgan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7712240/publications.pdf

Version: 2024-02-01

166 papers	10,147 citations	38720 50 h-index	36008 97 g-index
177 all docs	177 docs citations	177 times ranked	14414 citing authors

#	Article	IF	Citations
1	Oral 11Î²-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. European Journal of Endocrinology, 2022, 186, 441-455.	1.9	12
2	A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PETâ€"CT images: Initial analysis. Journal of Nuclear Cardiology, 2022, 29, 3315-3331.	1.4	7
3	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. Rheumatology, 2022, 61, 4935-4944.	0.9	3
4	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomicsâ€Driven</scp> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	1.5	15
5	A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts. Journal of Clinical Immunology, 2022, 42, 947-951.	2.0	21
6	OA13â€ƒComprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. Rheumatology, 2022, 61, .	0.9	0
7	P200â€ƒCombining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
8	OA24â€ƒPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
9	OA15â€ƒDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
10	P189â€ƒA longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	1
11	The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2377-2388.	1.8	18
12	Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study. Journal of Infectious Diseases, 2022, 226, 554-562.	1.9	5
13	OA26â€ƒErythrocyte mean corpuscular volume as a surrogate marker for methotrexate polyglutamation during early treatment in rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
14	OA16â€ƒTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0
15	Interplay between demographic, clinical and polygenic risk factors for severe COVID-19. International Journal of Epidemiology, 2022, 51, 1384-1395.	0.9	8
16	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Research and Therapy, 2021, 23, 80.	1.6	11
17	Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 1184-1191.	4.6	36
18	Evaluating tertiary adrenal insufficiency in rheumatology patients on longâ€term systemic glucocorticoid treatment. Clinical Endocrinology, 2021, 94, 361-370.	1.2	13

#	Article	IF	Citations
19	Association between age at disease onset of anti-neutrophil cytoplasmic antibodyâ€“associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	0.9	22
20	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology, 2020, 59, 1364-1371.	0.9	43
21	Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic. Lancet Rheumatology, The, 2020, 2, e386-e387.	2.2	3
22	Latent Class Trajectory Modeling of 2â€Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Diseaseâ€Modifying Antirheumatic Drugs. Arthritis and Rheumatology, 2020, 72, 1632-1642.	2.9	9
23	Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. Cmaj, 2020, 192, E295-E301.	0.9	43
24	Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNÎ³+LPS), M(IL-4) and M(IL-10) phenotypes. Journal of Immunological Methods, 2020, 478, 112721.	0.6	81
25	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Medicine, 2020, 17, e1003432.	3.9	111
26	Pharmacogenetics of TNF inhibitorÂresponse in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics, 2020, 21, 1151-1156.	0.6	3
27	Title is missing!. , 2020, 17, e1003432.		0
28	Title is missing!. , 2020, 17, e1003432.		0
29	Title is missing!. , 2020, 17, e1003432.		0
30	Title is missing!. , 2020, 17, e1003432.		0
31	Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3757-3767.	1.8	48
32	Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. Cmaj, 2019, 191, E680-E688.	0.9	53
33	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. PLoS ONE, 2019, 14, e0223246.	1.1	11
34	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Reports, 2019, 12, e229236.	0.2	8
35	010â€ƒTemporal artery biopsy: audit, scoring and reporting. Rheumatology, 2019, 58, .	0.9	0
36	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.5	25

#	Article	IF	Citations
37	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. Rheumatology, 2019, 58, 1684-1686.	0.9	3
38	A Multicenter, Randomized, Placeboâ€Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	2.9	77
39	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2019, 58, 1400-1409.	0.9	39
40	SAT0062â€…STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
41	FRI0017â€…DIFFERENTIAL METHYLATION AS A PREDICTOR OF TOCILIZUMAB RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
42	SAT0009â€…THE EFFECT OF FCGR3A POLYMORPHISM ON THE INITIAL DEPTH OF B-CELL DEPLETION BY RITUXIMAB, FUNCTIONAL NK-CELL MEDIATED KILLING AND CLINICAL RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
43	Giant cell arteritis: new concepts, treatments and the unmet need that remains. Rheumatology, 2019, 58, 1123-1125.	0.9	17
44	Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 589-595.	0.5	27
45	O12â€ƒValidity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
46	Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatmentâ€toâ€Target Era. Arthritis Care and Research, 2018, 70, 361-368.	1.5	12
47	Affimer proteins inhibit immune complex binding to FcÎ³RIIIa with high specificity through competitive and allosteric modes of action. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E72-E81.	3.3	36
48	Prediction of treatment response in rheumatoid arthritis patients using genomeâ€wide SNP data. Genetic Epidemiology, 2018, 42, 754-771.	0.6	15
49	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS ONE, 2018, 13, e0209343.	1.1	3
50	i006â€ƒRheumatologist perspective: management of uveitis and inflamatory eye diseases. Rheumatology, 2018, 57, .	0.9	0
51	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 657-664.	0.9	41
52	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	0.9	42
53	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. Rheumatology, 2017, 56, kew416.	0.9	3
54	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Annals of the Rheumatic Diseases, 2017, 76, 208-213.	0.5	49

#	Article	IF	Citations
55	Neonatal BehÃ§et's disease. Archives of Disease in Childhood, 2017, 102, 1062-1062.	1.0	0
56	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
57	Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. Journal of Rheumatology, 2017, 44, 1331-1340.	1.0	6
58	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology, 2017, 56, kew387.	0.9	10
59	I25â€ƒOverview of Stratified Medicine: What is it and what Examples are there of Successful Application?. Rheumatology, 2016, , .	0.9	0
60	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Medicine (United States), 2016, 95, e2368.	0.4	55
61	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1353-1360.	2.9	59
62	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology, 2016, 55, 2050-2055.	0.9	14
63	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritisâ€"results from the IDEA study. Rheumatology, 2016, 55, 2181-2190.	0.9	21
64	Previously reported PDE3Aâ€"SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics, 2016, 17, 715-720.	0.6	9
65	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Research and Therapy, 2015, 17, 195.	1.6	40
66	Rheumatoid arthritis response to treatment across IgG1 allotype â€" anti-TNF incompatibility: a case-only study. Arthritis Research and Therapy, 2015, 17, 63.	1.6	9
67	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Research and Therapy, 2015, 17, 359.	1.6	6
68	Curry-assisted diagnosis in the rheumatology clinic. Oxford Medical Case Reports, 2015, 2015, 297-299.	0.2	2
69	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology, 2015, 54, 494-499.	0.9	90
70	Validity and reliability of the Persian version of BehÃ§etâ€™s disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation. Rheumatology International, 2015, 35, 677-684.	1.5	4
71	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. JAMA - Journal of the American Medical Association, 2015, 313, 1645.	3.8	119
72	O49.â€ƒPersonalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritisâ€"Multi-Centre Prospective Cohort Studies. Rheumatology, 2015, , .	0.9	0

#	Article	IF	Citations
73	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
74	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, The, 2015, 385, S48.	6.3	18
75	Clinical Utility of Random Antiâ€"Tumor Necrosis Factor Drugâ€"Level Testing and Measurement of Antidrug Antibodies on the Longâ€Term Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	2.9	90
76	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	5.8	149
77	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 1387-1393.	0.5	69
78	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics Journal, 2014, 14, 171-175.	0.9	3
79	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 861-868.	1.5	71
80	MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. Pharmacogenomics, 2014, 15, 467-475.	0.6	16
81	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Annals of the Rheumatic Diseases, 2014, 73, 1202-1210.	0.5	166
82	Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2014, 66, 24-30.	2.9	41
83	Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2014, 73, 143-148.	0.5	65
84	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Annals of the Rheumatic Diseases, 2014, 73, 75-85.	0.5	139
85	Testing the role of vitamin D in response to antitumour necrosis factor Î± therapy in a UK cohort: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 2014, 73, 938-940.	0.5	6
86	Emergence of proinflammatory autoreactive T-cell responses in preclinical rheumatoid arthritis. Lancet, The, 2014, 383, S22.	6.3	3
87	Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Lancet, The, 2014, 383, S26.	6.3	0
88	342.â€ƒIs Plasma Viscosity an Acceptable Substitute for Erythrocyte Sedimentation Rate for the Diagnosis of Giant Cell Arteritis?. Rheumatology, 2014, 53, i188-i188.	0.9	0
89	Prediction model for rheumatoid arthritis: modelling 46 genetic risk variants with smoking. Lancet, The, 2013, 381, S97.	6.3	2
90	Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking. PLoS Genetics, 2013, 9, e1003808.	1.5	55

#	Article	IF	Citations
91	Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Metaâ€Analysis of Genomeâ€Wide Data. Arthritis and Rheumatism, 2013, 65, 3058-3062.	6.7	43
92	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	1.5	146
93	Allele dose association of theC5orf30rs26232 variant with joint damage in rheumatoid arthritis. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	20
94	Identification of thePTPN22functional variant R620W as susceptibility genetic factor for giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1882-1886.	0.5	51
95	Metaanalysis of the Association of Smoking andPTPN22R620W Genotype on Autoantibody Status and Radiological Erosions in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1048-1053.	1.0	15
96	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. PLoS Genetics, 2012, 8, e1003032.	1.5	78
97	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1350-1354.	0.5	39
98	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. Annals of the Rheumatic Diseases, 2012, 71, 1640-1645.	0.5	20
99	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A52.1-A52.	0.5	0
100	Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clinical and Experimental Immunology, 2012, 170, 36-46.	1.1	38
101	Investigation ofIL1,VEGF,PPARGandMEFVgenes in psoriatic arthritis susceptibility: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 313-314.	0.5	15
102	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Research and Therapy, 2012, 14, R214.	1.6	18
103	A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes and Immunity, 2012, 13, 120-128.	2.2	50
104	In situmacromolecular crystallography using microbeams. Acta Crystallographica Section D: Biological Crystallography, 2012, 68, 592-600.	2.5	113
105	Outrunning free radicals in room-temperature macromolecular crystallography. Acta Crystallographica Section D: Biological Crystallography, 2012, 68, 810-818.	2.5	83
106	Confirmation of association ofFCGR3Bbut notFCGR3Acopy number with susceptibility to autoantibody positive rheumatoid arthritis. Human Mutation, 2012, 33, 741-749.	1.1	36
107	Replication of association of the PTPRC gene with response to antiâ€"tumor necrosis factor therapy in a large UK cohort. Arthritis and Rheumatism, 2012, 64, 665-670.	6.7	65
108	FcÎ³RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. PLoS ONE, 2012, 7, e28918.	1.1	49

#	Article	IF	Citations
109	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, 43, 761-767.	9.4	778
110	Genomeâ€wide association study of genetic predictors of antiâ€"tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis and Rheumatism, 2011, 63, 645-653.	6.7	143
111	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.5	68
112	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1641-1644.	0.5	103
113	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2011, 70, 98-103.	0.5	55
114	Cardiovascular risk and rheumatoid arthritis--the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology, 2011, 50, 1944-1954.	0.9	35
115	Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 463-468.	0.5	130
116	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology, 2011, 50, 2014-2022.	0.9	31
117	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and Genomics, 2010, 20, 338-341.	0.7	12
118	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Annals of the Rheumatic Diseases, 2010, 69, 1572-1573.	0.5	32
119	Rheumatoid arthritis risk allele PTPRC is also associated with response to antiâ€"tumor necrosis factor Î± therapy. Arthritis and Rheumatism, 2010, 62, 1849-1861.	6.7	95
120	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
121	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	9.4	1,132
122	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Annals of the Rheumatic Diseases, 2010, 69, 1054-1057.	0.5	55
123	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Human Molecular Genetics, 2010, 19, 4544-4544.	1.4	0
124	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Annals of the Rheumatic Diseases, 2010, 69, 666-670.	0.5	73
125	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. Annals of the Rheumatic Diseases, 2010, 69, 1407-1408.	0.5	9
126	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology, 2010, 49, 1894-1899.	0.9	25

#	Article	IF	Citations
127	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFÂB signalling pathways. Annals of the Rheumatic Diseases, 2010, 69, 1315-1320.	0.5	74
128	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology, 2010, 49, 43-47.	0.9	9
129	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases, 2010, 69, 1029-1035.	0.5	89
130	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2199-2203.	0.5	36
131	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Annals of the Rheumatic Diseases, 2010, 69, 813-816.	0.5	62
132	Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. Arthritis Research and Therapy, 2010, 12, R57.	1.6	37
133	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Research and Therapy, 2010, 12, R175.	1.6	92
134	Angiogenesis and Giant Cell Arteritis. , 2010, , 383-402.		1
135	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Human Molecular Genetics, 2009, 18, 2518-2522.	1.4	78
136	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Human Molecular Genetics, 2009, 18, 2693-2699.	1.4	93
137	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 69-74.	0.5	240
138	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology, 2009, 48, 1369-1374.	0.9	20
139	Reevaluation of the interaction between HLAâ€"DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibodyâ€positive and autoantibodyâ€negative rheumatoid arthritis in a large UK Caucasian population. Arthritis and Rheumatism, 2009, 60, 2565-2576.	6.7	86
140	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nature Genetics, 2009, 41, 1313-1318.	9.4	306
141	A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1373-1375.	0.5	13
142	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenetics and Genomics, 2009, 19, 319-323.	0.7	35
143	The shared epitope hypothesis in rheumatoid arthritis: Evaluation of alternative classification criteria in a large UK Caucasian cohort. Arthritis and Rheumatism, 2008, 58, 1275-1283.	6.7	40
144	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nature Genetics, 2008, 40, 1156-1159.	9.4	143

#	Article	IF	Citations
145	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics, 2008, 17, 3532-3538.	1.4	111
146	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Human Molecular Genetics, 2008, 17, 2274-2279.	1.4	131
147	Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. Journal of Experimental Medicine, 2008, 205, 1573-1582.	4.2	213
148	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 299-306.	0.2	12
149	Asthma and airways collapse in two heritable disorders of connective tissue. Annals of the Rheumatic Diseases, 2007, 66, 1369-1373.	0.5	47
150	The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. Cancer Research, 2007, 67, 8444-8449.	0.4	284
151	Rheumatoid arthritis association at 6q23. Nature Genetics, 2007, 39, 1431-1433.	9.4	361
152	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Research and Therapy, 2006, 8, R109.	1.6	47
153	Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Research and Therapy, 2006, 8, R5.	1.6	39
154	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research, 2005, 7, R80.	2.0	75
155	Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. Journal of Rheumatology, 2005, 32, 1043-6.	1.0	50
156	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor Â variable genes in primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2004, 64, 468-470.	0.5	7
157	Fc? receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al. Arthritis and Rheumatism, 2004, 50, 1352-1353.	6.7	0
158	FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study. British Journal of Rheumatology, 2003, 42, 528-533.	2.5	46
159	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood, 2002, 100, 4550-4556.	0.6	152
160	Association of FcÎ³ receptor IIIA polymorphism with rheumatoid arthritis: Comment on the article by Morgan et al. Arthritis and Rheumatism, 2002, 46, 556-557.	6.7	3
161	Unique TCR Î²-subunit variable gene haplotypes in Africans. Immunogenetics, 2002, 53, 884-893.	1.2	4
162	Human immunodeficiency virus associated spondyloarthropathy: pathogenic insights based on imaging findings and response to highly active antiretroviral treatment. Annals of the Rheumatic Diseases, 2001, 60, 696-698.	0.5	31

#	Article	IF	Citations
163	Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting?. Eye, 2001, 15, 492-496.	1.1	5
164	FcÎ³ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis and Rheumatism, 2000, 43, 2328-2334.	6.7	103
165	Laboratory findings and pathology of psoriatic arthritis. Bailliere's Clinical Rheumatology, 1994, 8, 439-463.	1.0	7
166	O50â€ƒHigh Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	0